Clinical trials for neurodevelopmental disorders: At a therapeutic frontier

Science Translational Medicine

Volumn 8, Issue 321, 2016, Pages

  Jeste, Shafali S ^a   Geschwind, Daniel H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MAVOGLURANT; METABOTROPIC RECEPTOR ANTAGONIST;

ARTICLE; CLINICAL TRIAL (TOPIC); DOWN SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FMR1 GENE; FRAGILE X SYNDROME; GENE LOSS; GENE MUTATION; HUMAN; MENTAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PLACEBO EFFECT; PRIORITY JOURNAL; RETT SYNDROME; STUDY DESIGN; ANIMAL;

ANIMALS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; NEURODEVELOPMENTAL DISORDERS;

EID: 84954289332     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad9874     Document Type: Article

References (10)

1. E. Berry-Kravis, V. Des Portes, R. Hagerman, S. Jacquemont, P. Charles, J. Visootsak, M. Brinkman, K. Rerat, B. Koumaras, L. Zhu, G. M. Barth, T. Jaecklin, G. Apostol, F. von Raison, Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 8, 321ra5 (2016).
2. R. J. Hagerman, The physical and behavioral phenotype, in Fragile X Syndrome: Diagnosis, Treatment, and Research, R. J Hagerman, P. Hagerman, Eds. (Johns Hopkins Univ. Press. Baltimore, 2002), pp. 3-109.
3. M. R. Santoro, S. M. Bray, S. T. Warren, Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu. Rev. Pathol. 7, 219-245 (2012).
4. M. F. Bear, K. M. Huber, S. T. Warren, The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004).
5. S. Jacquemont, E. Berry-Kravis, R. Hagerman, F. von Raison, F.Gasparini, G.Apostol, M.Ufer, V.Des Portes, B.Gomez-Mancilla, The challenges of clinical trials in fragile X syndrome. Psychopharmacology 231, 1237-1250 (2014).
6. S. Jacquemont, A. Curie, V. des Portes, M. G. Torrioli, E. Berry-Kravis, R. J. Hagerman, F. J. Ramos, K. Cornish, Y. He, C. Paulding, G. Neri, F. Chen, N. Hadjikhani, D. Martinet, J. Meyer, J. S. Beckmann, K. Delange, A. Brun, G. Bussy, F. Gasparini, T. Hilse, A. Floesser, J. Branson, G. Bilbe, D. Johns, B. Gomez-Mancilla, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to themGluR5 antagonist AFQ056. Sci. Transl.Med. 3, 64ra1 (2011).
7. T. C. Dockendorff, H. S. Su, S. M. McBride, Z. Yang, C. H. Choi, K. K. Siwicki, A. Sehgal, T. A. Jongens, Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34, 973-984 (2002).
8. J. Levenga, S. Hayashi, F. M. de Vrij, S. K. Koekkoek, H. C. van der Linde, I. Nieuwenhuizen, C. Song, R. A. Buijsen, A. S. Pop, B. Gomezmancilla, D. L. Nelson, R. Willemsen, F. Gasparini, B. A. Oostra, AFQ056, a newmGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 42, 311-317 (2011).
9. I. Gantois, A. S. Pop, C. E. de Esch, R. A. Buijsen, T. Pooters, B. Gomez-Mancilla, F. Gasparini, B. A. Oostra, R. D'Hooge, R. Willemsen, Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav. Brain Res. 239, 72-79 (2013).
10. A. Masi, A. Lampit, N. Glozier, I. B. Hickie, A. J. Guastella, Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: A meta-analysis. Transl. Psychiatry 5, e640 (2015).